British pharmaceutical company AstraZeneca has been able to significantly increase its sales and profits in cancer drugs so far this year. However, the company is doing less and less business with the coronavirus vaccine.
Sales of cancer drugs rose by 17 percent to $12.7 billion (11.88 billion euros) in the first quarter compared to the same period last year, the British pharmaceutical company announced in Cambridge on Thursday.
The surplus rose by more than a fifth to $2.18 billion. According to analyst James Gordon of the JPMorgan bank, AstraZeneca exceeded market expectations at the beginning of this year. The confirmed annual outlook now appears conservative, the expert said.
Declines in corona vaccines
The trade in medicines for heart, kidney and metabolic diseases and rare diseases also increased. This more than compensated for the significant decline in sales of corona vaccines and medicines.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
